^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Multiple Myeloma

    11h
    Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2030 --> Mar 2031 | Initiation date: Dec 2025 --> Mar 2026
    Trial completion date • Trial initiation date
    |
    clonoSEQ
    |
    Xpovio (selinexor)
    11h
    Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University of Utah
    New trial
    11h
    A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases (clinicaltrials.gov)
    P1, N=30, Recruiting, Grit Biotechnology
    New P1 trial
    |
    CD19 (CD19 Molecule)
    16h
    MyeEx-Impact: Re-building bone with exercise in multiple myeloma (ACTRN12624000127505)
    P=N/A, N=78, Recruiting, University of Technology Sydney | Not yet recruiting --> Recruiting
    Enrollment open
    16h
    COSTA: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Cristiana Costa Chase, DO | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Blenrep (belantamab mafodotin-blmf)
    16h
    In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET (clinicaltrials.gov)
    P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Enrollment open • Trial completion date • Trial primary completion date
    17h
    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov)
    P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    20h
    GO39775: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=355, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Jan 2026 | Trial primary completion date: Apr 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    21h
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=20 --> 4
    Enrollment closed • Enrollment change • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    1d
    Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. (PubMed, Sci Rep)
    This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • ARID2 (AT-Rich Interaction Domain 2) • IRF4 (Interferon regulatory factor 4)
    |
    pomalidomide • Farydak (panobinostat)
    2d
    SAPPHIRE-MM: Exercise Therapy for Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=71, Not yet recruiting, University Hospital Heidelberg
    New trial
    2d
    Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors. (PubMed, Sci Adv)
    To demonstrate the usefulness of the method for immunotherapy applications, we investigated the interaction of primary multiple myeloma cells with the therapeutic monoclonal antibodies daratumumab and isatuximab and a polyclonal anti-CD38 antibody. Our approach might lay the foundation for improved personalized diagnostics and treatment with therapeutic antibodies.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule)
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)